Acotiamide
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Acotiamide
- Accession Number
- DB12482
- Description
Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.
- Type
- Small Molecule
- Groups
- Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More- Structure
Structure for Acotiamide (DB12482)
- Weight
- Average: 450.55
Monoisotopic: 450.193691256 - Chemical Formula
- C21H30N4O5S
- Synonyms
- Not Available
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcebutolol Acotiamide may increase the bradycardic activities of Acebutolol. Acetylcholine The risk or severity of adverse effects can be increased when Acotiamide is combined with Acetylcholine. Aclidinium Acotiamide may increase the neuromuscular blocking activities of Aclidinium. Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Acotiamide. Amifampridine The risk or severity of adverse effects can be increased when Acotiamide is combined with Amifampridine. Amitriptyline The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Acotiamide. Amobarbital The therapeutic efficacy of Amobarbital can be decreased when used in combination with Acotiamide. Amoxapine The therapeutic efficacy of Amoxapine can be decreased when used in combination with Acotiamide. Anisotropine methylbromide The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Acotiamide. Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Acotiamide. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Salicylamides
- Alternative Parents
- Methoxyphenols / Dimethoxybenzenes / 4-alkoxyphenols / Benzamides / Thiazolecarboxamides / Phenoxy compounds / 2-heteroaryl carboxamides / Benzoyl derivatives / Anisoles / 1-hydroxy-2-unsubstituted benzenoids show 11 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 2,4-disubstituted 1,3-thiazole / 2-heteroaryl carboxamide / 4-alkoxyphenol / Alkyl aryl ether / Amine / Amino acid or derivatives / Anisole / Aromatic heteromonocyclic compound / Azacycle show 30 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- salicylamides (CHEBI:34523)
Chemical Identifiers
- UNII
- D42OWK5383
- CAS number
- 185106-16-5
- InChI Key
- TWHZNAUBXFZMCA-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)
- IUPAC Name
- N-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-hydroxy-4,5-dimethoxybenzamido)-1,3-thiazole-4-carboxamide
- SMILES
- COC1=C(OC)C=C(C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C)C(O)=C1
References
- General References
- Not Available
- External Links
- KEGG Compound
- C14127
- PubChem Compound
- 5282338
- PubChem Substance
- 347828720
- ChemSpider
- 4445505
- ChEBI
- 34523
- ChEMBL
- CHEMBL2107723
- ZINC
- ZINC000002002237
- Wikipedia
- Acotiamide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Dyspepsia 1 3 Completed Treatment Dyspepsia / Functional Dyspepsia 1 Not Available Completed Other Healthy Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0191 mg/mL ALOGPS logP 3.12 ALOGPS logP 1.62 ChemAxon logS -4.4 ALOGPS pKa (Strongest Acidic) 8.24 ChemAxon pKa (Strongest Basic) 9.62 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 113.02 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 121.14 m3·mol-1 ChemAxon Polarizability 48.33 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 20, 2016 16:33 / Updated on June 12, 2020 10:53
